Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4780 Comments
1879 Likes
1
Tayson
Active Contributor
2 hours ago
{协议答案}
👍 168
Reply
2
Deadrian
Engaged Reader
5 hours ago
{协议答案}
👍 27
Reply
3
Maryjayne
Senior Contributor
1 day ago
{协议答案}
👍 280
Reply
4
Ishi
Influential Reader
1 day ago
{协议答案}
👍 135
Reply
5
Ashlie
New Visitor
2 days ago
{协议答案}
👍 247
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.